June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Distinct molecular mechanisms responsible for different retinopathies caused by CRX mutations DNH and LFH
Author Affiliations & Notes
  • Alan Zhang
    Ophthalmology, Washington University St. Louis, st louis, MO
  • Nicholas Tran
    Ophthalmology, Washington University St. Louis, st louis, MO
  • Xiaodong Zhang
    Ophthalmology, Washington University St. Louis, st louis, MO
  • Shiming Chen
    Ophthalmology, Washington University St. Louis, st louis, MO
  • Footnotes
    Commercial Relationships Alan Zhang, Howard Hugh Medical Institute (F), National Institute of Health (F), Washington University in St. Louis (E); Nicholas Tran, None; Xiaodong Zhang, None; Shiming Chen, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 1580. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Alan Zhang, Nicholas Tran, Xiaodong Zhang, Shiming Chen; Distinct molecular mechanisms responsible for different retinopathies caused by CRX mutations DNH and LFH. Invest. Ophthalmol. Vis. Sci. 2013;54(15):1580.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Mutations in the transcription factor CRX are associated with dominant retinopathies of varying severity in humans. We created two Knock-IN mouse models for CRX disease: Dominant-Negative High Expression (DNH) carries a 2-bp deletion at codon 168 resulting in a truncated CRX protein lacking the transactivation domains; Loss-of-function High Expression (LFH) carries an amino acid substitution, R90W in the DNA binding domain, compromising CRX’s ability to bind DNA. The Crx-DNH mouse models severe dominant Cone-Rod Dystrophy, while Crx-LFH models a recessive Leber Congenital Amaurosis. This study focuses on the distinct biochemical mechanisms by which the DNH and LFH proteins affect CRX target gene expression to cause distinct forms of CRX-associated disease.

Methods: Quantitative real time PCR (QRT-PCR) detected expression changes for selected CRX target genes in mutant vs WT retinas. Changes in DNA binding and transactivation activities of mutant vs WT CRX proteins were measured by retinal chromatin immunoprecipitation (ChIP), electrophoretic mobility shift assays (EMSA), and Rhodopsin and Crx promoter dual luciferase reporter assays in transiently transfected HEK293 cells.

Results: Crx-DNH/+ mice show severely decreased photoreceptor gene expression along with impaired rod and cone function and rapid retinal degeneration, while Crx-LFH/+ mice show normal retinal gene expression and function. Dual-luciferase assays revealed that neither LFH nor DNH protein can activate target gene expression in vitro and that DNH actively impairs WT CRX-mediated transactivation. EMSA showed DNH but not LFH binds DNA in vitro. Surprisingly, ChIP showed that DNH and LFH proteins both associate with the chromatin of CRX target genes in vivo. This supports our QRT-PCR findings that DNH/DNH cannot activate CRX target gene expression but LFH/LFH allows a low level of transcription.

Conclusions: DNH causes dominant disease by binding to DNA and interfering with WT CRX’s transactivation ability. LFH loses DNA binding and transactivation activity in vitro but can still associate with DNA in vivo to exert hypomorphic regulatory function. Crx DNH and LFH mice represent two mechanistically distinct models of CRX disease with vastly different pathologies, providing excellent models for testing novel therapeutic approaches.

Keywords: 739 transcription factors • 533 gene/expression • 494 degenerations/dystrophies  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×